Key Highlights
- The FDA approved Ionis Pharmaceuticals' zilganersen, branded as Zanvastro, as the first treatment for Alexander disease, a rare neurological disorder affecting fewer than 1,000 people in the US.
- The injectable drug can be used in both adult and pediatric patients and is administered into the spinal canal every three months by a trained healthcare professional.
- In a pivotal study, patients receiving a 50 mg dose showed a statistically significant improvement in gait speed at 61 weeks, as measured by a 10-meter walk test.
- Analysts have projected the drug could generate peak annual sales of $295 million.
A Landmark Approval for an Ultra-Rare Disease
The US Food and Drug Administration approved Ionis Pharmaceuticals' therapy to treat Alexander disease, a rare condition affecting the brain's white matter, making it the first treatment to receive approval for the genetic disorder. Ionis' injectable drug zilganersen, branded as Zanvastro, can be used to treat adults and pediatric patients with Alexander disease, a neurological disorder that damages brain cells and causes problems with movement, speech and swallowing, often beginning in early childhood.
The condition affects fewer than 1,000 people in the US, according to the National Institutes of Health. A director of the FDA's neurology division, which reviews treatments for rare genetic and neuromuscular diseases, called the approval a landmark moment for the patient community, offering the first therapy that addresses the underlying cause of the disease.
How the Drug Works
Zanvastro works by blocking the production of a protein called GFAP, which builds up abnormally in the brain due to a genetic mutation and contributes to the progression of the disease. It is administered as an injection into the spinal canal every three months by a trained healthcare professional. Ionis did not immediately respond to a request for comment on pricing details.
Clinical Trial Results Supporting the Approval
In the pivotal study supporting the approval, patients who received a 50 mg dose of Zanvastro showed a statistically significant and clinically meaningful improvement in gait speed, as assessed by a 10-meter walk test, at 61 weeks compared with a control group. The drug also demonstrated consistent benefit across key secondary endpoints evaluating adaptive function, communication, gastrointestinal symptoms, sleep and seizures, with a favorable safety and tolerability profile throughout the study.
A Milestone in Ionis' Neurology Pipeline
The approval represents Ionis' first independent commercial launch in neurology, an important milestone for the company as it seeks to strengthen its position in the field and deliver a steady stream of treatments for serious diseases. Zilganersen previously received Breakthrough Therapy, Orphan Drug and Rare Pediatric designations from the FDA, along with Orphan Drug designation from the European Medicines Agency, reflecting the urgency regulators placed on bringing a treatment to market given the absence of any prior approved options.
Analyst Expectations for the Drug's Commercial Potential
In an earlier note, analysts at an Investment bank projected the drug could generate peak annual sales of $295 million, reflecting the ultra-rare nature of the condition it treats. While that figure is modest compared with blockbuster therapies for more common diseases, it represents a meaningful new Revenue stream for Ionis and, more importantly, the first disease-modifying option available to patients and families who have had no approved treatments to turn to.
A New Option Where None Existed Before
For a patient population that has historically had no disease-modifying treatment options, the approval marks a significant shift, giving physicians and families access to a therapy that directly targets the underlying cause of Alexander disease rather than only managing its symptoms.






Please wait processing your request...